News | September 10, 2008

New MI Application Accelerates Pancreatic Cancer Detection

September 10, 2008 - Cellvizio in vivo cellular imaging technology is helping researchers detect early-stage pancreatic cancer, understand stem cell development and enhance the value of whole body imaging, according to three new animal studies being presented at the World Molecular Imaging Congress in Nice, France, held September 10-13, 2008.

According to results from two recently published studies on Cellvizio imaging of pancreatic cancer, the targeted molecular imaging approach and vascular monitoring method developed, respectively, by Ken Young Lin and colleagues at the Center for Molecular Imaging Research in Boston and Johannes von Burstin and colleagues at the Technical University of Munich.

The Cellvizio system, by Mauna Kea Technologies, provides microscopic visualization of mucosal tissue and improves clinical outcomes by increasing the diagnostic yield of existing endoscopic procedures. The growing in vivo cellular imaging market enabling physicians to visualize, diagnose and treat pathologies that can not be seen using other imaging techniques.

These methods promise to substantially increase the detection rates of early-stage pancreatic cancer. Because early diagnosis and therapy response evaluation are the prerequisite for curative surgery, the presented translational results offer the prospect of improving overall survival of pancreatic cancer patients. The first study was published in the July 2008 issue of Translational Oncology and the second appeared in the August 15 issue of International Journal of Cancer.

A promising technique for in vivo tracking of somatic stem cells and could lead to valuable insights for improving the success of bone marrow transplants.Daniel Lewandowski and colleagues from the French Atomic Energy Commission in Fontenay aux roses, France, demonstrated that with Cellvizio they were able to view live in vivo the cellular dynamics of somatic stem cell development without interfering in the process.

The connection between cancer and blot clots may also be clearer for researchers. Using Cellvizio, Grace Thomas and colleagues from the Center of Research in Biological Oncology and Oncopharmacology in Marseille, France, demonstrated that the development of a cancerous tumor directly influences kinetics of blood clot formation in vivo. Through in vivo cellular imaging of platelets and leukocytes with Cellvizio, they were able to observe that times to blockage of veins and arteries were all significantly reduced in mice developing a tumor in comparison with those observed in control mice. These results may provide insights on how to prevent the risk of blood clot complications associated with cancer.

Carine Pestourie and colleagues from the French Atomic Energy Commission in France showed that the combination of whole body imaging systems such as Positron Emission Tomography (PET) and Cellvizio provides a new tool to monitor quantitatively and dynamically the in vivo distribution of compounds, such as Quantum Dots, from whole body to cellular scales with low invasiveness. Such a combination could be used in the future to better diagnose human pathologies.

For more information:

Related Content

Novel PET Tracer Clearly Identifies and Tracks Bacterial Lung Infection

Representative PET/CT images of 18F-FDS and 18F-FDG in inflamed mice. Mice were inoculated with dead K. pneumoniae (10^8 CFU/mL). Imaging was performed for days 1, 2, 3 and 4 using 18F-FDG and 18F-FDS. CT images showed clear inflammation on day 2 and day 3 with corresponding high 18F-FDG uptake on PET. No significant uptake of 18F-FDS was detected for any of those 4 days. Credit: J Li et al., University of Louisville School of Medicine, Louisville, Ky.

News | PET-CT | January 22, 2018
January 22, 2018 — Researchers at the University of Louisville, Kentucky, have demonstrated that a new...
PET Tracer Gauges Effectiveness of Promising Alzheimer's Treatment

Longitudinal PET imaging with 18F-AV45. PET imaging shows the average 18F-AV45 uptake per animal group at 8 and 13 months of age. A significant interaction of genotype treatment was observed in the cortex (p = 0.0248), hippocampus (p = 0.0071) and thalamus (p = 0.0084), indicating reduced [18F]-AV45 uptake in BACE1 inhibited transgenic mice. Credit: MICA, University of Antwerp, Belgium.

News | Radiopharmaceuticals and Tracers | December 28, 2017
In the December featured basic science article in The Journal of Nuclear Medicine, Belgian researchers report on the...
Michael J. Fox Foundation and Tau Consortium Developing PET Tracers for Neurodegenerative Disease
News | Radiopharmaceuticals and Tracers | October 27, 2017
The Michael J. Fox Foundation for Parkinson's Research (MJFF) and the Tau Consortium announced a funding partnership to...
SNMMI Publishes New FDG PET/CT Appropriate Use Criteria
News | PET-CT | October 25, 2017
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has published appropriate use criteria (AUC) for FDG PET/...
Majority of Recurrent Prostate Cancer Patients' Treatment Plan Changed Following Fluciclovine 18F PET/CT
News | Prostate Cancer | October 04, 2017
Blue Earth Diagnostics recently announced the results of a pre-planned interim analysis from an investigational...
Toshiba Highlights Latest CT Advancements at RSNA 2017
News | Computed Tomography (CT) | September 18, 2017
Toshiba Medical announced that it will display several new enhancements to its existing computed tomography (CT)...
Double Targeting Ligands to Identify and Treat Prostate Cancer

The mice were imaged with small-animal PET/CT using 124I-RPS-027 (7.4 MBq [200 μCi]). Credit: JM Kelly et al., Department of Radiology, Weill Cornell Medicine, New York, NY

News | Prostate Cancer | September 14, 2017
Researchers have demonstrated a new, effective way to precisely identify and localize prostate cancer tumors while...
Blue Earth Diagnostics Announcing Results of FALCON PET/CT Trial at ASTRO 2017
News | PET-CT | September 13, 2017
September 13, 2017 — Blue Earth Diagnostics announced the upcoming oral presentation of initial results from the FALC
FDG-PET/CT Predicts Melanoma Patients' Response to Immune Checkpoint Inhibitor Therapy
News | PET-CT | September 07, 2017
September 7, 2017 — Advanced melanoma has a poor prognosis, but immune checkpoint inhibitor therapy can be effective
Videos | Nuclear Imaging | August 24, 2017
Prem Soman, M.D., director of nuclear cardiology at the Heart and Vascular Institute, University of Pittsburgh, and p
Overlay Init